NovoCure Total Current Liabilities

NovoCure Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

NovoCure's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

NovoCure's Total Current Liabilities for the quarter that ended in Mar. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

NovoCure Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of NovoCure's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure Business Description

Industry

Healthcare » Medical Devices & Instruments NAICS : 339112 SIC : 3845

Comparable Companies

NYSE:STVN NZSE:FPH NAS:RGEN NAS:XRAY MIL:AMP NYSE:ATR NAS:MASI NYSE:NVST NAS:AZTA LSE:CTEC

Traded in Other Exchanges

NVCR:Mexico 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Executives

Weinberg Uri	officer: Chief Science Officer	NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Groenhuysen Wilhelmus Cm	officer: Chief Operating Officer	C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654
Danziger Asaf	director, officer: Chief Executive Officer	5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302
Leung Gabriel	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960
Shah Pritesh	officer: Chief Commercial Officer	C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Leonard Frank X	officer: Chief Development Officer	20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Cordova Ashley	officer: Chief Financial Officer	20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Madden Martin J.	director	C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043
Benaim Ely	officer: Chief Medical Officer	C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Doyle William F	director, officer: Executive Chairman	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ambrogi Michael J.	officer: Chief Operating Officer	195 COMMERCE WAY PORTSMOUTH NH 03801
Longsworth Todd Christopher	officer: General Counsel	NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Hilleman Jeryl L	director	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mccoy Sherilyn S	director	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Hung David	director	C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018